With the precision of monoclonal antibodies and the potency of small-molecular payloads, antibody-drug conjugates (ADC) are promising cancer therapeutics. As of this year, there are 19 ADC drugs ...

Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.

While the race is on to develop antibody-drug conjugate (ADC) cancer treatments, so too is the competition to manufacture them. Hoping to gain an edge in the rapidly growing market are MilliporeSigma ...

Abzena, a U.K.-based CDMO, will pump $5 million into its Bristol, Pennsylvania, manufacturing site to help meet growing demand for services surrounding antibody-drug conjugates (ADCs) and other ...

Research-backed strategy produces highly homogeneous antibody-drug conjugates (gsADCs) with consistent DAR and tumor suppression lasting over 50 days after a single dose A new white paper from ...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc. and Charles River Laboratories, Inc. have announced a strategic alliance to offer complementary services to clients including early development and ...

The antibody-drug conjugate landscape is facing a critical inflection point. As it stands, manufacturing complexity could pose a threat to future innovation, despite the unmatched market demand. With ...